DEF: Kenvue's Board Outlines Strategy for Accelerated Growth in 2025 at Upcoming Annual Meeting

Kenvue's proxy statement highlights the company's progress in its first full year as an independent entity and outlines strategic priorities for future growth and shareholder value.

Summary

• Kenvue's Board of Directors invites shareholders to the 2025 Annual Meeting, reflecting on the company's first full year as an independent entity.
• The company completed nearly all planned Transition Service Agreement (TSA) exits, spanning over 2,000 agreements across 50 countries.
• Kenvue's 'Vue Forward' initiative, a two-year cost savings plan, aims to deliver $350 million in annualized savings by 2026 and remains on track.
• Brand investments increased by 20% in 2024 compared to 2023 due to cost-saving efforts.
• The Board has been refreshed with five new independent directors, following succession planning and a Cooperation Agreement with Starboard Value.
• Kenvue reported $15.5 billion in Net sales in 2024.
• The company operates in three segments: Self Care, Skin Health & Beauty, and Essential Health, selling products in over 165 countries.
• Approximately 50% of 2024 Net sales were generated outside North America.
• The Board recommends shareholders vote for the election of 13 director nominees, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent accounting firm for 2025.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both achievements and challenges. While sales growth was limited, cost-saving initiatives and strategic board changes suggest a positive outlook. The sentiment is cautiously optimistic.

Positives

• The company successfully exited over 2,000 transitional services across more than 50 countries without disruption to business operations.
• Kenvue drove meaningful productivity across the organization that resulted in strong Gross profit margin performance.
• The company is committed to returning capital to shareholders through its quarterly dividend.
• Employee engagement levels are above plan and above industry benchmarks.

Negatives

• Net sales performance was impacted by a slower-than-expected recovery in the Skin Health & Beauty business in the United States.
• Net sales performance was impacted by low cold, cough & flu, allergy and sun seasons.
• Net sales performance was impacted by a temporary disruption in the distributor network in the Asia Pacific region.
• Organic net sales and Free cash flow results fell short of annual incentive plan thresholds.
• Adjusted net income performance was below annual incentive plan target.

Risks

• The company faces risks related to the transfer of Deferred Local Businesses, including obtaining necessary governmental approvals.
• Kenvue is subject to covenants in the Tax Matters Agreement that impose restrictions designed to preserve the tax-free nature of the Separation and the Distribution.
• The company relies on J&J for certain services under the Transition Services Agreement and faces risks related to the transition of these services.
• Kenvue is required to indemnify J&J for certain liabilities, which could be significant.

Future Outlook

Kenvue believes it has a strong foundation to execute on its strategic priorities, unlock the full potential of its iconic brands, and deliver value for shareholders in 2025 and beyond.

Management Comments

• The management team remained laser focused on transitioning the Company's systems and processes to best suit the needs of a standalone consumer health company.
• Kenvue will be leaning into the distinct powers that set our brands apart from the cutting-edge science that underpins our innovations to new AI-enabled ways that make it easier for consumers to discover and shop our products.
• We are as motivated as ever to make Kenvue the undisputed global leader in consumer health.

Industry Context

Kenvue operates at the intersection of healthcare and consumer goods, positioning it uniquely in the consumer health market. The company's focus on science-backed brands and digital strategy aligns with industry trends towards personalized and accessible healthcare solutions.

Comparison to Industry Standards

• The document references a compensation peer group of 17 companies, including The Campbells Company, Church & Dwight Co., Inc., The Clorox Company, and Colgate-Palmolive Company, to benchmark executive compensation levels.
• Kenvue's Performance Peer Group includes 30 companies, including Beiersdorf AG, Brown-Forman Corporation, and Unilever PLC, to assess relative Total Shareholder Return (TSR).

Management Changes

Corporate Governance

Related Party Transactions

• Kenvue has entered into various agreements with J&J in connection with the Separation, including the Separation Agreement, Tax Matters Agreement, Employee Matters Agreement, Intellectual Property Agreement, Trademark Phase-Out License Agreement, Transition Services Agreement, and Transition Manufacturing Agreement.
• Kenvue paid Profitero, Ltd. approximately $1.2 million in 2024 for advertising and marketing services.
• Kenvue paid Circana approximately $7.6 million in 2024 for consumer data, analytics, and insights services.

Stakeholder Impact

• The company aims to deliver value for shareholders through strategic execution and growth.
• Kenvue is committed to nurturing healthy people, enriching a healthy planet, and maintaining healthy practices through its Healthy Lives Mission.
• The company's approximately 22,000 Kenvuers work every day to put the power of everyday care in consumers' hands.

Next Steps

• Shareholders will vote on the election of directors, approval of executive compensation, and ratification of the independent accounting firm at the Annual Meeting.
• Kenvue will continue to execute its strategic priorities, including engaging more consumers, freeing up resources for brand investment, and fostering a performance-driven culture.
• The company will continue to transition services from J&J and establish its own standalone functions.

Key Dates

Keywords

Kenvue, Annual Meeting, Proxy Statement, Board of Directors, Shareholders, Executive Compensation, Corporate Governance, Financial Performance, Strategy, Consumer Health